17 results about "Diabetic animal" patented technology

The application discloses application of Xintong preparation in preparation of a medicine for treating diabetes and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The Xintong preparation is prepared from 13 raw medicinal materials of Huangqi, Gegen, Danshen, Dangshen, Maidong, Heshouwu, Yinyanghuo, Dangui, Zaokesheng, Haizao, Kelp, Muli and Zhishi, has the effects of benefiting qi and activating blood, reducing phlegm and dredging collaterals. Pharmacodynamic experiments show that the Xintong preparation has the effect of reducing blood sugar, can effectively improve the physical conditions of polydipsia, polyphagia, polyuria and emaciation and lack of strength of an animal model of diabetes, significantly reduces the fasting blood sugar and serum insulin level, improves the oral glucose tolerance, has a definite treatment effect on type II diabetes, and expands the clinical application range of the Xintong preparation, and has a wide market application prospect.

The present invention belongs to the technical field of cell biology, and particularly relates to the application of Hippo-Yap pathway regulators in promoting the directed differentiation of induced pluripotent stem cells into pancreatic progenitor cells. The method of the present invention can efficiently obtain pancreatic progenitor cells derived from non-human primate rhesus monkeys in vitro, providing a material source for further obtaining functional pancreatic islet β cells of non-human primate rhesus monkeys, and more importantly, providing a practical basis for the autologous transplantation treatment of non-human primate diabetic animal models.

The invention discloses a method for constructing a diabetes animal model after hyperlipidemia type acute pancreatitis. The method comprises the following steps: S1, selecting male C57BL / 6N mice which are 7 weeks old, and feeding the male C57BL / 6N mice with hyperlipidemia; s2, injecting froglein into the abdominal cavity of the hyperlipemia mouse; s3, replacing drinking water of the mice with 5% sweet water, and testing fasting blood glucose and random blood glucose on the first day, the fourth day and the seventh day after the rain frog element is injected; s4, when the random blood glucose of the mouse is larger than or equal to 16.7 mmol / L or the fasting blood glucose of the mouse is larger than or equal to 11.1 mmol / L, the mouse And S5, killing the mouse with cervical vertebra dislocation, taking pancreatic tissues of the mouse, fixing the pancreatic tissues, performing HE staining, and if an acinus structure is damaged, cells are swelled and necrotic and a large number of inflammatory cells of interstitial substances are infiltrated, judging that the acute pancreatitis is molded. Meanwhile, if the conditions are met, it can be judged that the mouse is a diabetic mouse after hyperlipidemia type acute pancreatitis. The method can simulate the occurrence of diabetes mellitus after hyperlipemia type acute pancreatitis, and lays a good foundation for the research of diabetes mellitus after hyperlipemia type acute pancreatitis.

The present application relates to the field of pharmacology, in particular to the use of paeoniflorin-6'-O-benzene sulfonate for improving acinar atrophy, maintaining the stability of gland functional units, and repairing gland secretion function. The paeoniflorin-6'-O-benzene sulfonate can effectively improve the acinar atrophy of diabetic animals, and the effect is significantly better than that of paeoniflorin, and can be used for preparing a medicine for treating xeroma.

The invention discloses a novel BimBH3 mimic peptide analogue constructed on the basis of a nailing and fatty acid acylation dual-modification strategy and application of the novel BimBH3 mimic peptide analogue serving as a PTPN1 inhibitor to development of a long-acting hypoglycemic drug. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The invention provides the BimBH3 mimic peptide analogue with a novel structure, and the BimBH3 mimic peptide analogue is constructed by adopting a nailing and fatty acid acylation dual-modification strategy and has the structural general formula as shown in the formula I. The invention further provides a preparation method of the BimBH3 mimic peptide analogue. On the basis of a BimBH3 functional domain core sequence, the novel BimBH3 mimic peptide analogue has target inhibitory activity, metabolic stability and in-vivo action durability through second-site lysine substitution, N-terminal palmitic acid conjugation and fifth, sixth and ninth site glutamic acid side chain mediated synthesis ring nailing modification, and the synthesis ring nailing mode is molecular lactam cyclization. Experiments show that the compound can efficiently inhibit PTPN1 activity, has a long-acting hypoglycemic effect in a type 2 diabetes animal model, and has the potential of being developed into a long-acting antidiabetic drug which is administered once a week. The invention also discloses a solid-phase synthesis preparation method of the compound and application of the compound as a potential PTPN1 inhibitor drug.

The present application relates to the technical field of hydrogel composite scaffold, in particular to a layer-by-layer self-assembled oxygen-responsive liposome hydrogel composite scaffold and a preparation method, hydrophilic nerve growth factor (GDNF) is encapsulated in the aqueous internal region of the liposome, and low-oxygen-responsive vascular endothelial growth factor (VEGF) plasmid and polyarginine are coated by electrostatic adsorption layer by layer (LBL), so as to construct an intelligent responsive LBL double-drug cationic liposome; subsequently, hyaluronic acid-carboxymethyl cellulose sodium (HA-CMC) hydrogel is introduced to carry the liposome to form a double-drug composite scaffold, so as to enhance the adhesion and local release characteristics of the composite scaffold on the wound surface. In a diabetic animal model, the LBL liposome loaded on the HA / CMC hydrogel can significantly accelerate wound healing, promote collagen deposition, angiogenesis and nerve fiber regeneration, and regulate the polarization of macrophages to the repair phenotype, thereby reducing the inflammatory response and achieving functional tissue repair.

The invention relates to an engineered exosome drug delivery system with enhanced membrane fluidity as well as a preparation method and application of the engineered exosome drug delivery system. According to the system, unsaturated phospholipid is inserted into an exosome membrane, so that the membrane flowability of the exosome is enhanced on the premise of not damaging a natural structure and protein composition, and the entrapment efficiency of polypeptide proteins, nucleic acid and small-molecule chemical drugs is remarkably improved. The membrane fluidity is enhanced, the diffusivity, the cellular uptake efficiency and the transepithelial transport performance of the exosome in intestinal mucus are improved, and the physiological barrier of oral delivery can be effectively overcome. In type I and type II diabetes animal models, the system significantly improves the oral bioavailability of insulin and semaglutide, and shows an excellent blood sugar regulation effect. The preparation method is simple and convenient, the biocompatibility is good, and a novel delivery strategy with a good transformation prospect is provided for oral biological macromolecular and micromolecular chemical drugs.

The invention belongs to the technical field of biological medicine, and particularly relates to a noninvasive controllable flexible biological electronic patch for treating diabetic erectile dysfunction. The erectile dysfunction related to diabetes is difficult to recover due to long-term damage of a cavernous body microenvironment, traditional oral administration or cavernous body injection treatment has poor targeting, non-uniform distribution and complication risk, and long-term curative effect is difficult to realize. The invention provides a flexible and attachable bioelectronic patch which is used for noninvasively, painlessly and controllably adjusting an erectile tissue microenvironment. The device synergistically promotes local vascular active factor expression and endothelial repair through mild electrical stimulation, realizes uniform transdermal delivery of drug molecules, shows high delivery efficiency and cell activity, and significantly improves cavernous body blood flow and cell functions. In an in-vitro cell model and a diabetic animal model, the device shows better vascular regeneration and function recovery effects than traditional medicine or injection therapy.

The application relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model, and relates to the field of experimental animal models, and particularly relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model. The application aims at solving the problems of long modeling time, instability and easy change into a type 1 diabetes mellitus model of the existing type 2 diabetes mellitus animal model establishing method. The feed comprises desulfurization vibrio powder, symbiotic clostridium powder and high-fat high-sugar feed. The method comprises the following steps: drying desulfurization vibrio liquid and symbiotic clostridium liquid into powder, uniformly mixing the powder and the high-fat high-sugar feed, and extruding into a column shape by using an extrusion molding machine. The application significantly shortens the establishment time of the type 2 diabetes mellitus animal model, does not need to inject a high-dose STZ, and does not cause the type 1 diabetes mellitus model of absolute insulin deficiency of rats in the case of using a higher concentration of STZ induction. The induced type 2 diabetes mellitus feed is used for establishing the type 2 diabetes mellitus animal model.

The invention relates to the technical field of animal model construction, and particularly discloses a pharmaceutical composition and a method for constructing a diabetes animal model. The pharmaceutical composition provided by the invention is prepared from the following components in parts by weight: 350 to 450 parts of metformin, 150 to 250 parts of lycium barbarum polysaccharide, 70 to 140 parts of corn stigma polysaccharide and 8 to 15 parts of dendrobium officinale. The invention also provides a method for constructing a diabetic animal model, which comprises the step of screening animals susceptible to diabetes by adopting the pharmaceutical composition, and the method comprises the following specific steps: administering the pharmaceutical composition to the animals in an oral intragastric administration manner, and screening the animals susceptible to diabetes according to the blood glucose reduction values before and after administration of the animals 40-50 minutes later. According to the method for constructing the diabetic animal model, animals susceptible to diabetes can be screened out, then the diabetic animal model with good consistency and stability can be obtained in a short time, and the model construction success rate can reach 85% or above.

The present disclosure relates to a diabetic animal model and methods of constructing and using the same. In particular, the present disclosure relates to a diabetic animal model, wherein the insulin enhancer binding protein-1 (Isl-1) gene in the genome of the animal model comprises a mutation in an exon and encodes an Isl-1 polypeptide having at least one amino acid substitution compared to a wild-type Isl-1 polypeptide.

The present application provides a preparation method of a non-human mammal model of type 1 diabetes. Specifically, the present application induces islet beta cell destruction in a non-immunodeficient mouse by using T cells specifically targeting GAD, constructs T cell autoimmune type 1 diabetes in line with the actual pathogenesis, and has application prospects in the field of diabetes research.

The invention belongs to the technical field of medicine research, and particularly relates to application of nutgall or nutgall extract in preparation of antidiabetic medicine. Tests prove that the nutgall extract can remarkably reduce the blood glucose level of a diabetic animal model, and it is prompted that the nutgall extract can be used as a potential anti-diabetic medicine.

The invention relates to the technical field of biology, in particular to application of beta-hydroxybutyrylation modification in preparation of a medicine for treating diabetic retinopathy. According to the application, the inducer for promoting beta-hydroxybutyrylation modification is used for preparing the medicine for preventing and / or treating diabetic retinopathy. The application is based on an in-vitro experiment, and proves that after beta-hydroxybutyrate intervention, beta-hydroxybutyrate is modified by beta-hydroxybutyrylation, so that apoptosis of a mouse retinal ganglion cell strain induced by an advanced glycosylation end product can be reduced; western blot proves that beta-hydroxy butyrylation modification of cells in a ganglion cell layer and a photoreceptor cell layer is induced in the retina in a diabetic animal body after beta-hydroxybutyrate intervention, which shows that the diabetic retina can be prevented and treated by inducing and promoting beta-hydroxy butyrylation modification; the blank between the beta-hydroxyl butyrylation modification and the diabetic retinopathy in the existing research is filled.

The invention discloses application of STMP1 and an inhibitor thereof in preparation of a medicine for treating diabetic retinopathy. A mouse STMP1 knock-down / knock-out model (KO) is constructed by utilizing a CRISPR-Cas9 technology, comparison is performed in an STZ (streptozotocin) induced diabetes animal model, and a result shows that compared with a wild type (WT) mouse, a KO + STZ group mouse has better performance in the aspects of insulin secretion and insulin sensitivity; meanwhile, electrophysiological detection and eye movement reaction test detection show that the visual function of a KO + STZ mouse is obviously superior to that of a WT + STZ mouse, and it is indicated that STMP1 knock-down can have a protective effect on visual impairment caused by diabetic retinopathy. A novel intervention strategy and medicine taking STMP1 as a treatment target are established on the basis of STMP1, so that the pathological mechanism of diabetic retinopathy can be disclosed, and a safer treatment method and medicine with higher compliance can be provided for patients with diabetic retinopathy.

The invention provides a construction method and application of a type I diabetes animal model, and the construction method comprises the following steps: selecting 3-4 week old young rats, and feeding the selected young rats with a high-fat and high-sugar feed for 3-4 weeks; after the young rats are subjected to fasting for 6-12 h, streptozotocin slow-release liquid is injected into the young rats subjected to fasting; the blood glucose of the young rats is monitored once every day, and when the blood glucose concentration exceeds an index, it is determined that the type 1 diabetes mellitus animal model is established. According to the scheme, after the streptozotocin slow-release liquid is prepared and injected into the young rats, the in-vivo release speed of streptozotocin can be delayed, pancreatic islet inflammation of the young rats can be slowly induced, induction can be completed through one-time injection, the injection frequency of the young rats is reduced, the survival rate of the young rats is increased, and the survival rate of the young rats is increased. The method can be applied to experimental research on the aspect of type I diabetes of children, and a research model is provided for clinical research on the type I diabetes.

The present invention belongs to the field of biotechnology, relates to the field of induced cell differentiation technology, and specifically relates to a method for inducing autologous mesenchymal stem cells into islet β-like cells. First, the present invention extracts exosomes from the pancreatic tissue of neonatal calves, adds a mixture of β-nerve growth factor and vitamin B3 to prepare an islet β-like cell inducer, and then places mesenchymal stem cells in the islet β-like cell inducer for culture to induce the acquisition of islet β-like cells. The present invention can obtain islet β-like cells at low cost, environmentally friendly and efficiently, and the induced islet β-like cells are highly sensitive to sugar concentration in vivo and in vitro, can significantly reduce the blood sugar of diabetes and significantly prolong its survival period, and have no obvious toxic and side effects on diabetic animal models and normal human bodies, and have important potential clinical application value.